Miles Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Miles Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-750	Closed	-$235K	–	193
2019 Q2	$235K	Buy	750 +21	+3%	+$6.99K	0.19%	143
2019 Q1	$299K	Hold	729	–	–	0.26%	103
2018 Q4	$272K	Hold	729	–	–	0.27%	108
2018 Q3	$295K	Hold	729	–	–	0.24%	112
2018 Q2	$251K	Hold	729	–	–	0.15%	140
2018 Q1	$251K	Buy	+729	New	+$254K	0.14%	157
2017 Q3	–	Sell	-1,136	Closed	-$558K	–	217
2017 Q2	$558K	Hold	1,136	–	–	0.3%	60
2017 Q1	$440K	Buy	1,136 +425	+60%	+$158K	0.25%	64
2016 Q4	$261K	Sell	711 -155	-18%	-$58.9K	0.16%	102
2016 Q3	$348K	Sell	866 -299	-26%	-$120K	0.24%	69
2016 Q2	$407K	Buy	1,165 +331	+40%	+$127K	0.28%	80
2016 Q1	$301K	Buy	+834	New	+$344K	0.2%	114

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Miles Capital's REGN Position: Q3 2019 in Review

Miles Capital sold out of Regeneron Pharmaceuticals (REGN) in Q3 2019, closing a stake of 750 shares — an estimated $235K sold.

Miles Capital first reported a position in REGN in Q1 2016 and held it in 12 quarters. The position peaked at $558K in Q2 2017. 633 funds tracked by Wall St. Rank hold REGN as of Q3 2019.

Miles Capital reported no remaining Regeneron Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Miles Capital sold 750 Regeneron Pharmaceuticals shares in Q3 2019, an estimated $235K.
Miles Capital first reported a position in Regeneron Pharmaceuticals in Q1 2016 and held it in 12 quarters.
Miles Capital's Regeneron Pharmaceuticals position peaked at $558K in Q2 2017.
633 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2019.

Based on Miles Capital's 13F filing for Q3 2019, filed 7 Nov 2019.